Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudarshan Pharma Industries's ROE % for the quarter that ended in Mar. 2026 was 27.45%. Sudarshan Pharma Industries's PB Ratio for the quarter that ended in Mar. 2026 was 3.73.
Sudarshan Pharma Industries's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 7.36%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudarshan Pharma Industries ROE % Adjusted to Book Value Chart
BOM:543828 vs DOW: ROE % Adjusted to Book Value Comparison
For the Chemicals subindustry, Sudarshan Pharma Industries's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudarshan Pharma Industries ROE % Adjusted to Book Value vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Sudarshan Pharma Industries's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Sudarshan Pharma Industries's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 7.36% mean?
Sudarshan Pharma Industries (BOM:543828) has a ROE % Adjusted to Book Value of 7.36% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sudarshan Pharma Industries and its competitors.
Is Sudarshan Pharma Industries' ROE % Adjusted to Book Value too high?
Sudarshan Pharma Industries' current ROE % Adjusted to Book Value is 7.36%. Overall, Sudarshan Pharma Industries has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sudarshan Pharma Industries' ROE % Adjusted to Book Value compare to DOW?
Sudarshan Pharma Industries' ROE % Adjusted to Book Value of 7.36% can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Chemicals company?
A good ROE % Adjusted to Book Value depends on the Chemicals industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sudarshan Pharma Industries and its competitors. Sudarshan Pharma Industries's current ROE % Adjusted to Book Value is 7.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudarshan Pharma Industries stock overvalued right now?
Based on GuruFocus' analysis, Sudarshan Pharma Industries (BOM:543828) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.52, compared to a current price of ₹32.49 — trading 398.3% above its estimated fair value. The current ROE % Adjusted to Book Value is 7.36%. Sudarshan Pharma Industries' overall GF Score™ is 69/100 with 14 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Sudarshan Pharma Industries (BOM:543828), the current ROE % Adjusted to Book Value is 7.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sudarshan Pharma Industries (BOM:543828) Overvalued in 2026?
Based on GuruFocus' analysis, Sudarshan Pharma Industries stock appears to be overvalued.
The current stock price of ₹32.49 is trading 398.3% above its estimated GF Value™ of ₹6.52.
GuruFocus considers Sudarshan Pharma Industries to be Significantly Overvalued.
Key valuation signals for BOM:543828:
ROE % Adjusted to Book Value: 7.36%
GF Value™: ₹6.52 vs. price of ₹32.49 (398.3% above fair value)
No single metric tells the full story. See the BOM:543828 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sudarshan Pharma Industries Ltd operates in the pharmaceutical and chemical industries, focusing on specialty chemicals and intermediates used in pharmaceuticals, paints, food products, and adhesives. The Company has a presence domestically and internationally, participating regularly in trade fairs and exhibitions. The Company exports mainly to South East Asia, the Middle East, and North Africa. The Company also supplies generic pharmaceutical formulation as 'Make to order' for bulk supply to hospitals and related healthcare organisations. The company has one reportable segment of Specialty Chemicals.
69GF Score
Get the complete analysis for BOM:543828
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543828 has been successfully added to your 
